Zacks.com on MSN15h
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug's ...
Daily21h
Merck to stop trial evaluating Winrevair early in pulmonary arterial hypertension
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...
Merck & Company Hold Rating: Promising Drug Developments Amid Uncertain Financial Outlook
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...
Pulmonaryhypertensionnews.com16h
Early Winrevair trial end to allow all patients to start active treatment
Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...
appliedclinicaltrialsonline16h
Kazia Therapeutics Launches Clinical Trial Evaluating Paxalisib in Combination with Keytruda or Lynparza for the Treatment of Advanced Breast Cancer
John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...
appliedclinicaltrialsonline18h
Bexicaserin Produces Significant Seizure Reduction in PACIFIC OLE Trial for Developmental and Epileptic Encephalopathies
The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...